We report a patient with schizophrenia who suffered an acute exacerbation of psychosis when treated with buspirone to alleviate anxiety. This psychotic reaction appeared to be dose dependent. Discontinuing buspirone resulted in a rapid improvement of psychotic symptoms. Re-introduction of buspirone at a modest dose helped to alleviate anxiety without exacerbating his schizophrenic symptoms. The other case studies of psychosis due to buspirone are reviewed and possible mechanisms for this association are discussed, particularly the role of dopamine and serotonin.
Achamallah N.S., Decker D.H. (1991) Mania induced by fluoxetine in an adolescent patient (letter). Am J Psychiatr148: 1404
2.
Algeri S., De Luigi A., De Simoni M.G., Imeri L., Marconi M., Nava S., Perego C., Sacchetti G. (1988) Multiple and complex effects of buspirone on central dopaminergic system. Pharmacol Biochem Behav29: 823-826
3.
Barrett J.E., Hoffmann S.M., Olmstead S.N., Foust M.J., Harrod C., Weissman B.A. (1989) Behavioral and neurochemical effects of the serotonin 5-HT1A receptor ligand spiroxatrine. Psychopharmacology97: 319-325
4.
Bersani G., Bressa G.M., Meco G. et al. (1990) Combined serotonin-5-HT2 and dopamine-D 2 antagonism in schizophrenia : clinical extrapyramidal and neuroendocrine responses in a preliminary study with risperidone. Hum Psychopharmacol5: 225-231
5.
Bianchi G., Garattini S. (1988) Blockade of alpha2-adrenoreceptors by 1-(2-pyrimidinyl)-piperazine (PMP) in vivo, and its relation to the activity of buspirone. Eur J Pharmacol147: 343-350
6.
Bleich A., Brown S-L., Kahn R., van Praag H.M. (1988) The role of serotonin in schizophrenia. Schizophrenia Bull14: 297-315
7.
Brody D., Adler L.A., Kim T., Angrist B., Rotrosen J. (1990) Effects of buspirone in seven schizophrenic patients . J Clin Psychopharmacol10: 68-69
8.
Bruning G., Kaulen P., Schneider U., Baumgarten H.G. (1989) Quantitative autoradiographic distribution and pharmacological characterization of (3H)buspirone binding to sections from rat, bovine and marmoset brain. J Neural Transm78: 131-144
9.
Ceulemans D L S, Gelders Y., Hoppenbrouwers M.L., Reyntjens A., Janssen P. (1985a) Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone. Psychopharmacology85: 329-332
10.
Ceulemans D L S, Van Doren J., Nuyts J., DeWit P. (1985b) Therapeutic efficacy of serotonin and dopamine antagonism on positive and negative symptoms of chronic schizophrenic patients . Proceedings of the Fourth World Congress of Biological Psychiatry. Philadelphia, PA. Biol Psychiatr 26: 272
11.
Chouinard G., Steiner W. (1986) A case of mania induced by high-dose fluoxetine treatment (letter). Am J Psychiatr143: 686
D'Mello D A., McNeil J.A., Harris W. (1989) Buspirone suppression of neuroleptic-induced akathisia: multiple case reports. J Clin Psychopharmacol9: 151-152
14.
Eison M.S. (1989) Azapirones: clinical use of serotonin partial agonists . Family Practice Recertification.11 (No. 9, Suppl.): September
15.
Eison A.S., Temple D.L. (1986) Buspirone: review of its pharmacology and perspectives on its mechanism of action. Am J Med80 (Suppl. 3B): 1-9
16.
Fletcher P.J., Davies M. (1990) The involvement of the 5-hydroxytryptaminergic and dopaminergic mechanisms in the eating induced by buspirone, gepirone and ipsapirone. Br J Pharmacol99: 519-525
17.
Gaddum J.H. (1954) Drugs antagonistic to 5-hydroxytryptamine. In Wolstenholme G W (ed.), Ciba Foundation symposium on hypertension. Little Brown and Company, Boston, pp. 75-77
18.
Gelders Y., Ceulemans D L S, Hoppenbrouwers M.L., Reyntjens A., Mesotten F. (1985a) Ritanserin, a selective serotonin antagonist in chronic schizophrenia. Proceedings of the Fourth World Congress of Biological Psychiatry. Philadelphia, PA. Biol Psychiatr 26: 338
19.
Gelders Y., Ceulemans D L S, Reyntjens A., Hoppenbrouwers M.L., Ferange M. (1985b) The influence of selective serotonin antagonism on conventional neuroleptic therapy. Proceedings of the Fourth World Congress of Biological Psychiatry. Philadelphia, PA. Biol Psychiatr 26: 417
20.
Gelernter J., van Kammen D.P. (1988) Schizophrenia: instability in norepinephrine, serotonin, and τ-aminobutyric acid systems. Int Rev Neurobiol29: 309-347
21.
Glazer W.M., Charney D.S., Heninger G.R. (1987) Noradrenergic function in schizophrenia. Arch Gen Psychiatr44: 898-904
22.
Goa K.L., Ward A. ( 1986) Buspirone: a preliminary review of its pharmacologic properties and therapeutic efficacy as an anxiolytic. Drugs32: 114-129
23.
Hogarty G.E., Anderson C.M., Reiss D.J., Kornblith S.J., Greenwald D.P., Javna C.D., Madonia M.J. (1986) Family psychoeducation, and social skills training and maintenance chemotherapy in the aftercare treatment of schizophrenia: I. One year effects of a controlled study on relapse and expressed emotion . Arch Gen Psychiatr43: 633-642
24.
Hollister L.E., Csernansky J.G. (1990) Clinical pharmacology of psychotherapeutic drugs (3rd edn). Churchill Livingstone , New York
25.
Hon D., Preskorn S.H. (1989) Mania during fluoxetine treatment for recurrent depression (letter). Am J Psychiatr146: 1638-1639
26.
Jann M.W., Froemming J.H., Borison R.L. (1990) Movement disorders and new azapirone anxiolytic drugs. Am Board Family Practitioners3: 111-119
27.
Jenner P., Sheehy M., Marsden C.D. (1983) Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: Implications for the treatment of Parkinson's disease. Br J Clin Pharmacol15(Suppl.): 2779-2898
28.
Kahn J.P., Puertollano M.A., Schane M.D., Klein D.F. (1988) Adjunctive alprazolam for schizophrenia with panic anxiety: clinical observation and pathogenetic implications. Am J Psychiatr145: 742-744
29.
Kamien J.B., Woolverton W.L. (1990) Buspirone blocks the discriminative stimulus effects of apomorphine in monkeys. Pharmacol Biochem Behav35: 117-120
30.
Lader M. (1987) Assessing the potential for buspirone dependence and abuse and effects of withdrawal. Am J Med82(Suppl. 5A): 20-26
31.
Lebegue B. (1987) Mania precipitated by fluoxetine (letter). Am J Psychiatr144: 1620
32.
Leff J. ( 1985) Family treatment of schizophrenia. In Granville-Grossman K (ed.), Recent advances in clinical psychiatry, Vol. 5. The Pitman Press, Bath, pp. 23-44
33.
Liebman J.M., Gerhadt S.C., Gerber R. (1989) Effects of 5-HT1A agonists and 5-HT 2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology97: 456-461
34.
Liegghio N.E., Yeragani V.K. (1988) Buspirone-induced hypomania: a case report. J Clin Psychopharmacol8: 226-227
35.
Mandalos G.E., Szarek B.L. (1990) Dose-related paranoid reaction associated with fluoxetine. J Nerv Mental Disord178: 57-58
36.
McDaniel J.S., Ninan P.T., Magnuson J.V. (1990) Possible induction of mania by buspirone. Am J Psychiatr147: 125-126
McMillen B.A., Mattias L.A. (1983) Comparative neuropharmacology of buspirone and MJ-13805, a potential anti-anxiety drug. J Neural Transm57: 255-265
39.
Mead Johnson Pharmaceutical Division (1986 ) Buspar. Manuscript, Evansville, Indiana : Mead Johnson Pharmaceutical Division, 53.
40.
Meltzer H.Y. (1991) The mechanism of action of novel antipsychotic drugs. Schizophrenia Bull17: 263-287
41.
Meltzer H.Y., Flemming R., Robertson A. (1983) The effect of buspirone on prolactin and growth hormone secretion in man. Arch Gen Psychiatr40: 1099-1102
42.
Nader M.A., Barrett J.E. (1989) Neurochemical changes in pigeon cerebrospinal fluid during chronic administration of buspirone or 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Pharmacol Biochem Behav32: 227-232
43.
Nakra B R S, Szwabo P., Grossberg G.T. (1989) Mania induced by fluoxetine (letter). Am J Psychiatr146: 1515-1516
44.
Nash J.F., Meltzer H.Y. (1989) Effect of gepirone and ipsapirone on the stimulated and unstimulated secretion of prolactin in the rat. J Pharmacol Exp Ther249: 236-241
45.
Newton R.E., Marunycz J.D., Alderdice M.T., Napoliello M.J. (1986) Review of the side-effect profile of buspirone . Am J Med80(Suppl. 3B): 17-21
46.
Pierce P.A., Peroutka S.J. (1989) Hallucinogenic drug interaction with neurotransmitter receptor binding sites in human cortex. Psychopharmacology97: 118-122
Robinson D.S., Rickels K., Feighner J., Fabre L.F., Gammans R.E. (1990) Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol10: 67S-76S
49.
Ross C.A. (1987) Buspirone in the treatment of tardive dyskinesia . Med Hypotheses22: 321-328
50.
Sathananthan G.L., Sanghvi I., Phillips N., Bershon S. (1975) MJ 9022: correlation between neuroleptic potential and stereotypy. Curr Ther Res18: 701-715
51.
Schweizer E.E., Amsterdam J., Rickels K., Kaplan M., Droba M. (1986) Open trial of buspirone in the treatment of major depressive disorder. Psychopharmacol Bull22: 183-185
52.
Settle E.C. Jr, Settle P. (1984) A case of mania associated with fluoxetine. Am J Psychiatr141: 280-281
53.
Sholomskas A.J. (1990) Mania in a panic disorder patient treated with fluoxetine (letter). Am J Psychiatr147: 1090-1091
54.
Sovner R., Parnell-Sovner N. (1989) Use of buspirone in the treatment of schizophrenia . J Clin Psychopharmacol9: 61-62
55.
Steiner W. (1991) Fluoxetine-induced mania in a patient with obsessive-compulsive disorder (letter). Am J Psychiatr148: 1403-1404
56.
Sternberg D.E., Charney D.S., Heninger G.R., Leckman J.F., Hafstad K.M., Landis D.H. (1982) Impaired presynaptic regulation of norepinephrine in schizophrenia: Effects of clonidine in schizophrenic patients and normal controls. Arch Gen Psychiatr39: 285-289
57.
Sullivan R.M., Henke P.G., Ray A. ( 1988) The effects of buspirone, a selective anxiolytic, on stress ulcer formation in rats. Pharmacol Biochem Behav31: 317-319
58.
Strauss A. (1988) Oral dyskinesia associated with buspirone use in an elderly woman. J Clin Psychiatr49: 322-323
59.
Taylor D.P. (1988) Buspirone, a new approach to the treatment of anxiety . FASEB J2: 2445-2452
60.
Van Kammen D.P., Peters J., Yao J., Van Kammen W.B., Neylan T., Shaw D., Linnoila M. (1990) Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited. Arch Gen Psychiatr47: 161-168
61.
Wander T.J., Nelson A., Okazaki H., Richelson E. (1987) Antagonism by neuroleptics of serotonin 5-HT 1A and 5-HT2 receptors of normal human brain in vitro. Eur J Pharmacol143: 279-282
62.
Wood P.L., Nair N.P., Lal S., Etienne P. (1983) Buspirone: a potential atypical neuroleptic. Life Sci33: 269-273
63.
Woolley D.W., Shaw E.A. (1954) A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA40: 228-231
64.
Yocca F. (1990) Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT1A receptors. J Clin Psychopharmacol10: 6S-12S
